Unnamed: 0,title,date,stock,sentiment
1109952.0,Revance And Mylan To Advance Development Program For Biosimilar To BOTOX; $30M Milestone Payable To Revance From Mylan,2020-06-01 08:34:00-04:00,RVNC,neutral
1109953.0,"Revance Announces Agreement To Acquire HintMD, Will Pay HintMD Shareholders Total Of 8.5M Shares",2020-05-19 08:10:00-04:00,RVNC,positive
1109954.0,"Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C.  and Los Angeles County.",2020-05-13 12:49:00-04:00,RVNC,negative
1109955.0,Revance Therapeutics Q1 EPS $(1.150) Misses $(0.900) Estimate,2020-05-07 16:12:00-04:00,RVNC,negative
1109956.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,RVNC,negative
1109957.0,"Revance Therapeutics Reports Mylan Biosimilar To BOTOX Program Decision To Extend Beyond Apr. 30, 2020",2020-05-01 08:30:00-04:00,RVNC,positive
1109958.0,"Stifel Maintains Buy on Revance Therapeutics, Lowers Price Target to $31",2020-04-16 11:02:00-04:00,RVNC,negative
1109959.0,"Mizuho Maintains Buy on Revance Therapeutics, Lowers Price Target to $35",2020-04-01 07:50:00-04:00,RVNC,negative
1109960.0,"H.C. Wainwright Reiterates Buy on Revance Therapeutics, Lowers Price Target to $24",2020-03-27 08:05:00-04:00,RVNC,negative
1109961.0,"Goldman Sachs Downgrades Revance Therapeutics to Neutral, Lowers Price Target to $15",2020-03-23 05:00:00-04:00,RVNC,negative
1109962.0,"Piper Sandler Reiterates Overweight on Revance Therapeutics, Raises Price Target to $40",2020-02-25 09:21:00-05:00,RVNC,negative
1109963.0,"Needham Maintains Buy on Revance Therapeutics, Raises Price Target to $36",2020-02-25 06:18:00-05:00,RVNC,neutral
1109964.0,"Revance Therapeutics Q4 EPS $(0.99) Misses $(0.98) Estimate, Sales $89K Does Not Comapre To $2.29M Estimate",2020-02-24 16:09:00-05:00,RVNC,negative
1109965.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,RVNC,neutral
1109966.0,Stocks That Hit 52-Week Highs On Friday,2020-02-21 10:26:00-05:00,RVNC,neutral
1109967.0,"The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion",2020-02-21 07:46:00-05:00,RVNC,negative
1109968.0,Stocks That Hit 52-Week Highs On Thursday,2020-02-20 10:26:00-05:00,RVNC,neutral
1109969.0,"Piper Sandler Maintains Overweight on Revance Therapeutics, Lowers Price Target to $37",2020-02-18 08:13:00-05:00,RVNC,negative
1109970.0,94 Biggest Movers From Yesterday,2020-02-12 05:13:00-05:00,RVNC,neutral
1109971.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,RVNC,positive
1109972.0,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",2020-02-07 07:32:00-05:00,RVNC,negative
1109973.0,Stocks That Hit 52-Week Highs On Thursday,2020-02-06 10:39:00-05:00,RVNC,neutral
1109974.0,Revance Therapeutics Reports FDA Accepted Biologics License Application For DAXI To Treat Frown Lines,2020-02-06 08:15:00-05:00,RVNC,positive
1109975.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,RVNC,negative
1109976.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-05 10:16:00-05:00,RVNC,neutral
1109977.0,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",2020-02-05 07:43:00-05:00,RVNC,neutral
1109978.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-04 10:18:00-05:00,RVNC,neutral
1109979.0,"Mizuho Maintains Buy on Revance Therapeutics, Raises Price Target to $39",2020-01-23 08:13:00-05:00,RVNC,neutral
1109980.0,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",2020-01-17 08:07:00-05:00,RVNC,negative
1109981.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-16 10:22:00-05:00,RVNC,neutral
1109982.0,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics",2020-01-16 07:22:00-05:00,RVNC,neutral
1109983.0,"The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance",2020-01-15 08:22:00-05:00,RVNC,negative
1109984.0,"The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug",2020-01-14 07:55:00-05:00,RVNC,positive
1109985.0,55 Biggest Movers From Friday,2020-01-13 05:17:00-05:00,RVNC,neutral
1109986.0,40 Stocks Moving In Friday's Mid-Day Session,2020-01-10 12:29:00-05:00,RVNC,neutral
1109987.0,"Revance Therapeutics Signs US Distribution Agreement With TEOXANE SA, Making Revance The Exclusive Commercialization Partner Of The Swiss Company's Hyaluronic Acid Technology",2020-01-10 08:10:00-05:00,RVNC,positive
1109988.0,"Revance Therapeutics Offers Corporate, Product Pipeline Update; Shares Anticipated 2020 Milestones",2020-01-09 08:13:00-05:00,RVNC,positive
1109989.0,Revance Therapeutics Reports Publication Of Pooled Results From Phase 3 Trials For Glabellar Lines In Journal Of American Academy Of Dermatology,2019-12-05 08:06:00-05:00,RVNC,neutral
1109990.0,72 Biggest Movers From Yesterday,2019-12-05 05:10:00-05:00,RVNC,neutral
1109991.0,Mid-Afternoon Market Update: Dow Rises Over 200 Points; Barnes & Noble Education Shares Slide,2019-12-04 14:36:00-05:00,RVNC,positive
1109992.0,38 Stocks Moving In Wednesday's Mid-Day Session,2019-12-04 12:02:00-05:00,RVNC,neutral
1109993.0,Mid-Day Market Update: Crude Oil Up 4%; Revance Therapeutics Shares Plunge,2019-12-04 12:02:00-05:00,RVNC,negative
1109994.0,Mid-Morning Market Update: Markets Open Higher; G-III Apparel Reports Mixed Q3 Results,2019-12-04 10:26:00-05:00,RVNC,neutral
1109995.0,Revance Therapeutics shares are trading lower after the company priced its 6.5 million share common stock offering at $17 per share.,2019-12-04 08:44:00-05:00,RVNC,positive
1109996.0,Revance Therapeutics Prices 6.5M Share Common Stock Offering At $17/Share,2019-12-04 07:41:00-05:00,RVNC,positive
1109997.0,26 Stocks Moving in Wednesday's Pre-Market Session,2019-12-04 07:24:00-05:00,RVNC,neutral
1109998.0,"The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug",2019-12-04 07:06:00-05:00,RVNC,negative
1109999.0,"8 Stocks To Watch For December 4, 2019",2019-12-04 04:37:00-05:00,RVNC,neutral
1110000.0,Revance shares are trading lower after the company announced a proposed public offering of common stock with no disclosed size.,2019-12-03 16:05:00-05:00,RVNC,negative
1110001.0,Revance Announces Proposed Public Offering Of Common Stock; Size Not Disclosed,2019-12-03 16:01:00-05:00,RVNC,neutral
1110002.0,75 Biggest Movers From Yesterday,2019-12-03 05:48:00-05:00,RVNC,neutral
1110003.0,44 Stocks Moving In Monday's Mid-Day Session,2019-12-02 12:11:00-05:00,RVNC,neutral
1110004.0,"Benzinga's Top Upgrades, Downgrades For December 2, 2019",2019-12-02 09:53:00-05:00,RVNC,positive
1110005.0,"Goldman Sachs Initiates Coverage On Revance Therapeutics with Buy Rating, Announces $25 Price Target",2019-12-02 06:20:00-05:00,RVNC,neutral
1110006.0,Revance Therapeutics Highlights Submission Of Biologics License Application To FDA For DAXI To Treat Glabellar Lines,2019-11-25 08:16:00-05:00,RVNC,positive
1110007.0,"The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More",2019-11-24 16:19:00-05:00,RVNC,positive
1110008.0,"Revance Therapeutics Q3 EPS $(0.96) Beats $(0.98) Estimate, Sales $46K Miss $430K Estimate",2019-11-04 16:37:00-05:00,RVNC,negative
1110009.0,"Revance Therapeutics Highlights Publication Of SAKURA 1, 2 Results In Plastic, Reconstructive Surgery: Showed Injection Can Reduce Frown Lines For 24 Weeks Or More",2019-11-04 08:23:00-05:00,RVNC,neutral
1110010.0,Wells Fargo Turns Bullish On Revance Therapeutics After Meeting With Management,2019-10-30 13:09:00-04:00,RVNC,positive
1110011.0,"Wells Fargo Upgrades Revance Therapeutics to Outperform, Raises Price Target to $20",2019-10-30 07:29:00-04:00,RVNC,positive
1110012.0,64 Biggest Movers From Yesterday,2019-10-15 05:07:00-04:00,RVNC,neutral
1110013.0,Revance Announces Mark Foley President and CEO After Dan Browne Resigns,2019-10-14 08:09:00-04:00,RVNC,negative
1110014.0,"The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved",2019-08-28 07:31:00-04:00,RVNC,positive
1110015.0,40 Healthcare Stocks Moving In Friday's After-Market Session,2019-07-29 04:25:00-04:00,RVNC,neutral
1110016.0,"Barclays Initiates Coverage On Revance Therapeutics with Overweight Rating, Announces $28 Price Target",2019-06-11 07:05:00-04:00,RVNC,negative
1110017.0,28 Stocks Moving In Thursday's Pre-Market Session,2019-05-09 08:08:00-04:00,RVNC,neutral
1110018.0,"The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut",2019-05-09 07:56:00-04:00,RVNC,neutral
1110019.0,"Revance Therapeutics Q1 EPS $(0.85) Beats $(0.87) Estimate, Sales $278K Miss $1.14M Estimate",2019-05-08 16:33:00-04:00,RVNC,negative
1110020.0,"The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split",2019-05-08 07:53:00-04:00,RVNC,negative
1110021.0,"The Daily Biotech Pulse: Merck's Keytruda Clinches Another FDA Win, KemPharm Close To NDA Filing For ADHD Drug",2019-04-12 07:47:00-04:00,RVNC,positive
1110022.0,"The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug",2019-04-11 07:48:00-04:00,RVNC,positive
1110023.0,"The Daily Biotech Pulse: Amgen's Bone-Building Osteoporosis Drug Clears FDA Muster, PhaseBio Offering",2019-04-10 07:32:00-04:00,RVNC,positive
1110024.0,Revance Therapeutics To Present SAKURA 3 Trial Results Presented on Podium at World's Largest Medical Aesthetic Conference,2019-04-08 16:07:00-04:00,RVNC,neutral
1110025.0,"Revance Therapeutics Q4 EPS $(1.12) Misses $(0.94) Estimate, Sales $487K Miss $1.3M Estimate",2019-02-26 17:28:00-05:00,RVNC,negative
1110026.0,"The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote",2019-02-26 07:56:00-05:00,RVNC,positive
1110027.0,"Benzinga's Top Upgrades, Downgrades For February 15, 2019",2019-02-15 09:16:00-05:00,RVNC,positive
1110028.0,Wells Fargo Initiates Coverage On Revance Therapeutics with Market Perform Rating,2019-02-15 08:42:00-05:00,RVNC,positive
1110029.0,"H.C. Wainwright Initiates Coverage On Revance Therapeutics with Buy Rating, Announces $25 Price Target",2019-02-14 07:31:00-05:00,RVNC,neutral
1110030.0,"Benzinga's Top Upgrades, Downgrades For January 29, 2019",2019-01-29 09:15:00-05:00,RVNC,positive
1110031.0,"Stifel Nicolaus Initiates Coverage On Revance Therapeutics with Buy Rating, Announces $50 Price Target",2019-01-29 07:52:00-05:00,RVNC,neutral
1110032.0,"Revance Therapeutics Shares Indicated Up 1.8% On Light Volume As Hearing Stifel Initiated Coverage With Buy Rating, $50 Price Target",2019-01-28 16:30:00-05:00,RVNC,positive
1110033.0,"Stocks Which Set New 52-Week Low Mon., Jan. 28, 2019",2019-01-28 15:33:00-05:00,RVNC,negative
1110034.0,48 Biggest Movers From Yesterday,2019-01-18 05:06:00-05:00,RVNC,neutral
1110035.0,34 Stocks Moving In Thursday's Mid-Day Session,2019-01-17 12:45:00-05:00,RVNC,neutral
1110036.0,22 Stocks Moving In Thursday's Pre-Market Session,2019-01-17 07:58:00-05:00,RVNC,neutral
1110037.0,Revance Prices ~5.882M Share Common Stock Offering At $17/Share,2019-01-17 06:58:00-05:00,RVNC,positive
1110038.0,58 Biggest Movers From Yesterday,2019-01-17 05:27:00-05:00,RVNC,neutral
1110039.0,40 Stocks Moving In Wednesday's Mid-Day Session,2019-01-16 12:31:00-05:00,RVNC,neutral
1110040.0,Revance Therapeutics shares are trading lower after the company announced a $100 million common stock offering.,2019-01-16 10:35:00-05:00,RVNC,neutral
1110041.0,"The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen",2019-01-16 08:24:00-05:00,RVNC,neutral
1110042.0,25 Stocks Moving In Wednesday's Pre-Market Session,2019-01-16 08:12:00-05:00,RVNC,neutral
1110043.0,"10 Stocks To Watch For January 16, 2019",2019-01-16 04:51:00-05:00,RVNC,neutral
1110044.0,8 Stocks Moving In Tuesday's After-Hours Session,2019-01-15 17:01:00-05:00,RVNC,neutral
1110045.0,"Revance Therapeutics 8-K Shows Co. Had ~$194.8M In Cash, Cash Equivalents, Short-Term Investments As Of Jan. 11, 2019",2019-01-15 16:58:00-05:00,RVNC,neutral
1110046.0,Revance Reports $100M Common Stock Offering,2019-01-15 16:17:00-05:00,RVNC,neutral
1110047.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,RVNC,neutral
1110048.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,RVNC,positive
1110049.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,RVNC,positive
1110050.0,"The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan",2018-12-18 08:00:00-05:00,RVNC,positive
1110051.0,50 Biggest Movers From Tuesday,2018-12-06 05:17:00-05:00,RVNC,neutral
1110052.0,Mid-Afternoon Market Update: Dow Drops Over 700 Points; Barnes & Noble Education Shares Plunge,2018-12-04 15:26:00-05:00,RVNC,positive
1110053.0,40 Stocks Moving In Tuesday's Mid-Day Session,2018-12-04 13:14:00-05:00,RVNC,neutral
1110054.0,Revance Therapeutics shares are trading up 16.1% after the company announced a license agreement with Fosun Pharma for its RT002 neuromodulator; Revance will receive an upfront payment of $30 million and tiered royalties on future sales.,2018-12-04 12:53:00-05:00,RVNC,positive
1110055.0,"UPDATE: Revance To Do New Trials For RT002 Related To Forehead Lines, Lateral Canthal Lines (Crow's Feet)",2018-12-04 08:15:00-05:00,RVNC,neutral
1110056.0,"UPDATE: Revance Reports RT002 'well-tolerated across over 3,800 treatments in glabellar (frown) lines'",2018-12-04 08:15:00-05:00,RVNC,neutral
1110057.0,"UPDATE: Revance Will Receive Upfront Payment Of $30M, Be Eligible To Receive Added Potential Development, Sales Milestone Payments Of $230.5M",2018-12-04 08:09:00-05:00,RVNC,neutral
1110058.0,"Revance Therapeutics Reports China Market License Deal With Fosun Pharma For RT002; Issues Another Press Release Highlighting RT002 Showed Fficacy, Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program",2018-12-04 08:09:00-05:00,RVNC,neutral
1110059.0,Revance Therapeutics Shares Halted News Pending,2018-12-04 08:03:00-05:00,RVNC,positive
1110060.0,"Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018",2018-11-28 11:54:00-05:00,RVNC,negative
1110061.0,"The Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings",2018-11-28 07:46:00-05:00,RVNC,neutral
1110062.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018",2018-11-27 11:26:00-05:00,RVNC,negative
1110063.0,"The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO",2018-11-21 08:04:00-05:00,RVNC,negative
1110064.0,"Stocks Which Set New 52-Week Lows Fri., Nov. 16, 2018",2018-11-19 10:16:00-05:00,RVNC,negative
1110065.0,"Guggenheim Upgrades Revance Therapeutics to Buy, Announces $41 Price Target",2018-11-16 08:23:00-05:00,RVNC,neutral
1110066.0,"Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 14, 2018",2018-11-15 11:37:00-05:00,RVNC,negative
1110067.0,"The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results",2018-11-15 08:10:00-05:00,RVNC,positive
1110068.0,74 Biggest Movers From Friday,2018-11-05 04:36:00-05:00,RVNC,neutral
1110069.0,64 Stocks Moving In Friday's Mid-Day Session,2018-11-02 12:44:00-04:00,RVNC,neutral
1110070.0,"Revance Therapeutics Q3 EPS $(0.91) Beats $(0.97) Estimate, Sales $2.362M Beat $370K Estimate",2018-11-01 17:11:00-04:00,RVNC,neutral
1110071.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,RVNC,negative
1110072.0,"Stocks Which Set New 52-Week Low Yesterday, October 29th",2018-10-30 12:40:00-04:00,RVNC,negative
1110073.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-10-27 10:23:00-04:00,RVNC,neutral
1110074.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,RVNC,negative
1110075.0,Revance Therapeutics Appoints Tobin C. Schilke As Chief Financial Officer,2018-10-11 08:31:00-04:00,RVNC,neutral
1110076.0,50 Biggest Movers From Yesterday,2018-09-18 06:18:00-04:00,RVNC,neutral
1110077.0,JMP: Changing Competitive Landscape Makes Revance Less Appealing,2018-09-17 16:11:00-04:00,RVNC,positive
1110078.0,36 Stocks Moving In Monday's Mid-Day Session,2018-09-17 12:27:00-04:00,RVNC,neutral
1110079.0,"Stocks Which Set New 52-Week Low Friday, September 14",2018-09-17 09:30:00-04:00,RVNC,negative
1110080.0,"Benzinga's Top Upgrades, Downgrades For September 17, 2018",2018-09-17 09:13:00-04:00,RVNC,positive
1110081.0,JMP Securities Downgrades Revance Therapeutics to Market Perform,2018-09-17 06:52:00-04:00,RVNC,positive
1110082.0,"Revance Therapeutics Q2 EPS $(0.94), Inline, Sales $686K Beat $510K Estimate",2018-08-02 16:52:00-04:00,RVNC,neutral
1110083.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,RVNC,positive
1110084.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,RVNC,neutral
1110085.0,Revance Doses 1st Patient In ASPEN Phase 3 Clinical Program of RT002,2018-06-21 16:05:00-04:00,RVNC,neutral
1110086.0,"Jefferies Global Healthcare Begins Today, Presenters Include: Kadmon, Aeri Pharma, Chemed, Orthofix, Revance, Heron Therapeutics, and Dicerna Pharma",2018-06-05 08:55:00-04:00,RVNC,neutral
1110087.0,42 Biggest Movers From Yesterday,2018-05-30 05:30:00-04:00,RVNC,neutral
1110088.0,"Revance Says CFO Lauren Silvernail Resigned As CFO, Says Certain Members Of Co.'s Existing Finance Team Will Assume Duties And Responsibilities Of The Office As They Begin A Search For Its Next CFO",2018-05-29 09:43:00-04:00,RVNC,neutral
1110089.0,Revance Therapeutics Reports Previously-Issued Results Of Phase 2 Study Of RT002 To Treat Moderate-To-Severe Cervical Dystonia Published In 'Movement Disorders Clinical Practice',2018-05-24 16:21:00-04:00,RVNC,positive
1110090.0,"UBS Global Healthcare Conference 2018 Continues Today, Presenters Include: Civitas Solutions, Revance, Akebia Therapeutics, Bristol-Myers, Senseonics, Lantheus, Acceleron Pharma, and HCA Healthcare",2018-05-22 07:05:00-04:00,RVNC,positive
1110091.0,"Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure",2018-05-08 07:55:00-04:00,RVNC,neutral
1110092.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,RVNC,neutral
1110093.0,Revance Therapeutics Expands Commercialization Team Ahead of Product Launch of RT002 Injectable,2018-04-02 16:15:00-04:00,RVNC,positive
1110094.0,"Barclays Global Healthcare Conference Concludes Today, Presenters Include: Tenet Healthcare, bluebird bio, and Revance Therapeutics",2018-03-15 09:14:00-04:00,RVNC,neutral
1110095.0,Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts,2018-03-13 16:32:00-04:00,RVNC,neutral
1110096.0,Goldman Sachs Sees 100% Upside In This Biopharma Company,2018-03-05 15:30:00-05:00,RVNC,neutral
1110097.0,"Benzinga's Top Upgrades, Downgrades For March 5, 2018",2018-03-05 09:13:00-05:00,RVNC,positive
1110098.0,"Goldman Sachs Initiates Coverage On Revance Therapeutics with Buy Rating, Announces $60.00 Price Target",2018-03-05 08:39:00-05:00,RVNC,neutral
1110099.0,"RBC Capital Global Healthcare Conference Begins Today, Presenters Include: Chemed, Revance, Eagle Pharma, Enanta, Gilead, TransEnterix, Immunogen, and Incyte",2018-02-21 07:14:00-05:00,RVNC,neutral
1110100.0,"13F From Perceptive Advisors Late Wednesday Shows Increased Stake In Abiomed, Neurocrine Biosciences, VBI Vaccines; New Stake In Agile Therapeutics, Amgen, bluebird bio, Arena Pharma, Revance Therapeutics; Exited Stake In Achaogen, OraSure Technologies",2018-02-15 10:41:00-05:00,RVNC,positive
1110101.0,"Barclays Injects Allergan With An Upgrade, Says Valuation Model Has Improved",2018-01-29 10:39:00-05:00,RVNC,positive
1110102.0,Too Few Visible Catalysts For Revance Push Guggenheim to The Sidelines,2018-01-09 17:44:00-05:00,RVNC,neutral
1110103.0,"Benzinga's Top Upgrades, Downgrades For January 9, 2018",2018-01-09 09:29:00-05:00,RVNC,positive
1110104.0,Guggenheim Downgrades Revance Therapeutics to Neutral,2018-01-09 07:59:00-05:00,RVNC,neutral
1110105.0,Revance Therapeutics Shares Down 5.372%; Earlier Co. Announced Did Not Meet Endpoints In Phase 2a Trial Of RT002,2018-01-08 11:38:00-05:00,RVNC,positive
1110106.0,Revance Therapeutics Sees FY18 Cash Burn $117M-$137M,2018-01-04 08:35:00-05:00,RVNC,neutral
1110107.0,Revance Sees 'Plantar Fasciitis Phase 2a Interim Results by Mid-January',2018-01-04 08:34:00-05:00,RVNC,neutral
1110108.0,Revance Therapeutics Says 'Expects to Complete RT002 SAKURA Phase 3 Program and Start RT002 Phase 3 Trial for Cervical Dystonia in 2018',2018-01-04 08:34:00-05:00,RVNC,neutral
1110109.0,7 Notable Biotechs With Data Expected By Year's End,2017-12-29 15:16:00-05:00,RVNC,neutral
1110110.0,31 Stocks Moving In Thursday's Mid-Day Session,2017-12-07 12:24:00-05:00,RVNC,neutral
1110111.0,Botox Competition Spurs Argus To Downgrade Allergan,2017-12-07 12:18:00-05:00,RVNC,neutral
1110112.0,Revance Prices 5.33M Share Offering At $31/Share,2017-12-07 08:34:00-05:00,RVNC,positive
1110113.0,"Guggenheim Initiates Coverage On Revance Therapeutics with Buy Rating, Announces $42.00 Price Target",2017-12-06 10:09:00-05:00,RVNC,neutral
1110114.0,36 Biggest Movers From Yesterday,2017-12-06 05:19:00-05:00,RVNC,neutral
1110115.0,Revance Announce $175M Proposed Stock Offering,2017-12-05 16:47:00-05:00,RVNC,neutral
1110116.0,Mid-Afternoon Market Update: Francesca's Drops On Earnings Miss; Revance Therapeutics Shares Gain,2017-12-05 14:31:00-05:00,RVNC,positive
1110117.0,30 Stocks Moving In Tuesday's Mid-Day Session,2017-12-05 13:59:00-05:00,RVNC,neutral
1110118.0,Mid-Day Market Update: Barnes & Noble Education Surges After Q2 Results; Ascena Retail Shares Slide,2017-12-05 12:45:00-05:00,RVNC,positive
1110119.0,Mid-Morning Market Update: Markets Mostly Higher; Toll Brothers Misses Q4 Views,2017-12-05 10:15:00-05:00,RVNC,negative
1110120.0,Revance Therapeutics Resumes Trading up ~39% After Meeting Endpoints,2017-12-05 08:01:00-05:00,RVNC,neutral
1110121.0,"Revance's RT002 Met Primary and All Secondary Endpoints, Achieves 6-Month Duration in Pivotal SAKURA Phase 3 Trials for Glabellar Lines",2017-12-05 07:32:00-05:00,RVNC,neutral
1110122.0,Revance Plans Phase 3 Program for RT002 Injectable,2017-11-29 16:26:00-05:00,RVNC,neutral
1110123.0,"Analyst Says Negative Allergan Headlines Are Priced In, Upgrades Stock",2017-11-29 08:48:00-05:00,RVNC,negative
1110124.0,"Barclays Initiates Coverage On Revance Therapeutics with Overweight Rating, Announces $31.00 Price Target",2017-11-27 08:07:00-05:00,RVNC,negative
1110125.0,Revance Therapeutics Reports Orphan Drug Designation For RT002 As Treatment For Cervical Dystonia,2017-11-20 16:07:00-05:00,RVNC,neutral
1110126.0,"Benzinga's Top Upgrades, Downgrades For November 17, 2017",2017-11-17 09:07:00-05:00,RVNC,positive
1110127.0,"Mizuho Initiates Coverage On Revance Therapeutics with Buy Rating, Announces $37.00 Price Target",2017-11-17 06:15:00-05:00,RVNC,neutral
1110128.0,"Revance Therapeutics Director Foley Buys 20,000 @ Avg Price: $26.96 -Form4",2017-11-09 19:57:00-05:00,RVNC,neutral
1110129.0,Revance Sees FY17 Cash Burn $102M-$112M,2017-11-02 17:48:00-04:00,RVNC,neutral
1110130.0,"Revance Reports Q3 EPS $(1.01) vs $(0.93) Est., Sales $75K vs $50K Est.",2017-11-02 17:48:00-04:00,RVNC,neutral
1110131.0,"Benzinga's Top Upgrades, Downgrades For August 22, 2017",2017-08-22 09:23:00-04:00,RVNC,positive
1110132.0,"JMP Securities Initiates Coverage On Revance Therapeutics with Market Outperform Rating, Announces $34.00 Price Target",2017-08-22 08:00:00-04:00,RVNC,positive
1110133.0,"Revance Reports Q2 EPS $(0.90) vs $(0.94) Est., Sales $75K",2017-08-03 17:02:00-04:00,RVNC,neutral
1110134.0,15 Biggest Mid-Day Gainers For Friday,2017-07-21 12:22:00-04:00,RVNC,neutral
1110135.0,"Benzinga's Top Upgrades, Downgrades For July 21, 2017",2017-07-21 09:27:00-04:00,RVNC,positive
1110136.0,"Cantor Fitzgerald Initiates Coverage On Revance Therapeutics with Overweight Rating, Announces $50.00 Price Target",2017-07-21 06:09:00-04:00,RVNC,negative
1110137.0,Revance Therapeutics Reports Positive BELMONT Phase 2 Trial Results Published in Dermatologic Surgery Journal,2017-06-15 08:01:00-04:00,RVNC,positive
1110138.0,"Revance Reports 'positive' Efficacy Results From RT002 Phase 2 Trial, Showed Clinically Significant Mean Reduction In Primary Endpoint",2017-06-05 16:06:00-04:00,RVNC,positive
1110139.0,Revance Therapeutics Reports Top-Line 24-Week Duration of Effect Results in All 3 Cohorts in RT002 Injectable Phase 2 Trial,2017-05-18 16:09:00-04:00,RVNC,neutral
1110140.0,"Revance Therapeutics Reaffirms FY17 Outlook: Cash Burn $102M-$112M, Opex $108M-$119M",2017-05-09 17:43:00-04:00,RVNC,neutral
1110141.0,"Revance Reports Q1 EPS $(0.94) vs $(0.85) Est., Sales $75K vs $70k Est.",2017-05-09 17:25:00-04:00,RVNC,neutral
1110142.0,UPDATE: Revance Says is Expanding Phase 2 Program for RT002 to Multi-Center Study with Protocol Updates,2017-05-01 07:32:00-04:00,RVNC,neutral
1110143.0,Revance Therapeutics Reports Update on Phase 2 Program for RT002 Injectable in Mgmt of Plantar Fasciitis,2017-05-01 07:31:00-04:00,RVNC,neutral
1110144.0,"Revance Therapeutics Says on March 14, 2017 Co Entered Into Services Agreement With Ajinomoto Althea, Inc; Under Agreement,Althea Has Agreed to Provide Co With Future Source of Commercial Fill/Finish Services for Neuromodulator Products -8-K",2017-03-15 06:12:00-04:00,RVNC,positive
1110145.0,"Revance Reports Q4 EPS $(0.95) vs. $(0.84) Est., Sales $75K vs. $70k Est.",2017-02-27 16:14:00-05:00,RVNC,neutral
1110146.0,Revance Expects Cash Burn Of $102-$112M For FY17,2017-01-05 16:08:00-05:00,RVNC,neutral
1110147.0,Revance Announces Positive 24-Week Duration of Effect in Interim Results from Phase 2 Cervical Dystonia Trial,2016-12-12 16:08:00-05:00,RVNC,positive
1110148.0,"Revance Announces Initiation of Subject Dosing in the SAKURA Phase 3 Clinical Program of RT002 Injectable for the Treatment of Glabellar Lines, Expects Topline Results Q4 2017",2016-12-07 08:10:00-05:00,RVNC,neutral
1110149.0,Revance Announces Initiation of Dosing for SAKURA Phase 3 Trial,2016-12-07 08:10:00-05:00,RVNC,neutral
1110150.0,Benzinga's Top Initiations,2016-11-29 09:21:00-05:00,RVNC,positive
1110151.0,"Aegis Capital Initiates Coverage On Revance Therapeutics at Buy, Announces $28.00 Target",2016-11-29 07:59:00-05:00,RVNC,neutral
1110152.0,"Revance Reports Q3 EPS $(0.64) vs. Est. $(0.89), Rev. $75K vs. Est. $70K",2016-11-03 17:32:00-04:00,RVNC,neutral
1110153.0,Revance Announces Initiation of Phase 2 Trial of RT002 Injectable to Treat Plantar Fasciitis,2016-11-03 08:01:00-04:00,RVNC,positive
1110154.0,Revance Reports Q2 EPS $(0.88) vs. Est $(0.86),2016-08-04 17:14:00-04:00,RVNC,neutral
1110155.0,"Revance Announces Completion of Pre-Phase 3 Meeting with FDA for RT002 Injectable to Treat Glabellar Lines, Plans To Initiate Phase 3 Program 2H 2016",2016-07-14 16:02:00-04:00,RVNC,positive
1110156.0,Mid-Afternoon Market Update: Crude Oil Down Over 1%; Motorcar Parts of America Shares Spike Higher,2016-06-14 14:38:00-04:00,RVNC,negative
1110157.0,9 Biggest Mid-Day Losers For Tuesday,2016-06-14 13:06:00-04:00,RVNC,negative
1110158.0,Mid-Day Market Update: Yingli Green Energy Surges Following Q1 Earnings; Infinity Pharmaceuticals Shares Tumble,2016-06-14 12:08:00-04:00,RVNC,positive
1110159.0,Stocks Hitting 52-Week Lows,2016-06-14 10:25:00-04:00,RVNC,negative
1110160.0,Mid-Morning Market Update: Markets Mostly Lower; Isle of Capri Casinos Profit Beats Views,2016-06-14 10:06:00-04:00,RVNC,positive
1110161.0,Brean Downgrades Revance Therapeutics Following RT-001 Fail,2016-06-14 08:53:00-04:00,RVNC,negative
1110162.0,Benzinga's Top Downgrades,2016-06-14 08:53:00-04:00,RVNC,positive
1110163.0,12 Stocks Moving In Tuesday's Pre-Market Session,2016-06-14 08:19:00-04:00,RVNC,neutral
1110164.0,Brean Capital Downgrades Revance Therapeutics to Hold,2016-06-14 06:01:00-04:00,RVNC,neutral
1110165.0,7 Stocks You Should Be Watching Today,2016-06-14 04:01:00-04:00,RVNC,neutral
1110166.0,3 Biotechs Posting Big Moves In Monday's After-Hours Session,2016-06-13 16:50:00-04:00,RVNC,neutral
1110167.0,Revance Therapeutics Shares to Resume Trade at 4:30 p.m. EDT,2016-06-13 16:22:00-04:00,RVNC,positive
1110168.0,"Revance Therapeutics Reports Results of RT001 Topical Phase 3 Trial: Did Not Achieve Co-Primary, Other Endpoints",2016-06-13 16:01:00-04:00,RVNC,neutral
1110169.0,Revance Therapeutics Shares Halted News Pending,2016-06-13 16:00:00-04:00,RVNC,positive
1110170.0,Brean Reiterates Buy Rating On Revance Ahead Of Upcoming Phase 3 Read-Out,2016-05-24 10:11:00-04:00,RVNC,neutral
1110171.0,"Revance Therapeutics Reports Q1 EPS $(0.71) vs $(0.83) Est., Sales $75K vs $70K Est.",2016-05-09 17:49:00-04:00,RVNC,neutral
1110172.0,"SunTrust Robinson Humphrey Initiates Coverage on Revance Therapeutics at Buy, Announces $46.00 PT",2016-03-23 08:28:00-04:00,RVNC,neutral
1110173.0,"Brean Capital Initiates Coverage on Revance Therapeutics at Buy, Announces $48.00 PT",2016-03-16 16:21:00-04:00,RVNC,neutral
1110174.0,Revance Announces Late-Breaking Podium Presentation of Positive 6-Month Duration Results for BELMONT Phase 2 Active Comparator Study of Injectable RT002 at AAD,2016-03-05 20:09:00-05:00,RVNC,positive
1110175.0,"Revance Therapeutics Reports Q4 EPS $(0.83) Vs Est $(0.86), Sales $75.0K Vs Est $60.0K",2016-03-02 16:10:00-05:00,RVNC,neutral
1110176.0,UPDATE: Revance Therapeutics Expects Dec 31 2015 Cash & Investment Balance To Be Over $250M,2016-01-07 16:52:00-05:00,RVNC,neutral
1110177.0,"Revance Specifies 2016 Clinical Program Milestones, Expects RT001 Topical And RT002 Injectable To Be In Phase 3 Programs In 2016",2016-01-07 16:10:00-05:00,RVNC,neutral
1110178.0,Mid-Morning Market Update: Markets Edge Lower; Cal-Maine Misses Q2 Expectations,2015-12-24 10:08:00-05:00,RVNC,negative
1110179.0,Watch These Four Stocks On Christmas Eve Morning,2015-12-24 07:23:00-05:00,RVNC,neutral
1110180.0,Revance Therapeutics Reports Phase 2 Results from RT001 Botulinum Toxin Type A Topical Gel for Treatment of Axillary Hyperhidrosis: Both Doses Show Measurable Reduction in Underarm Sweating,2015-12-23 16:06:00-05:00,RVNC,neutral
1110181.0,"Revance Names Abhay Joshi, PhD, as COO",2015-12-14 16:06:00-05:00,RVNC,neutral
1110182.0,Revance Therapeutics 13D Filing Shows Holder JP Morgan Chase Holds 10.4% Stake AS Of Nov 30th,2015-12-07 16:11:00-05:00,RVNC,positive
1110183.0,Benzinga's Top Initiations,2015-11-23 09:43:00-05:00,RVNC,positive
1110184.0,"Guggenheim Securities Initiates Coverage on Revance Therapeutics at Buy, Announces $55.00 PT",2015-11-23 08:09:00-05:00,RVNC,positive
1110185.0,"Revance Therapeutics Reports Q3 EPS $(0.81) vs. Est. $(1.01), Rev. $75K vs. Est. $90K",2015-11-09 16:04:00-05:00,RVNC,neutral
1110186.0,Revance Therapeutics Prices 3.25M Share Offering @$36.00/Share,2015-11-04 04:23:00-05:00,RVNC,positive
1110187.0,Mid-Day Market Update: Dyax Jumps On Acquisition News; Endurance International Shares Dip,2015-11-02 12:17:00-05:00,RVNC,positive
1110188.0,Mid-Morning Market Update: Markets Open Higher; Visa To Acquire Visa Europe,2015-11-02 10:04:00-05:00,RVNC,neutral
1110189.0,Morning Market Losers,2015-11-02 09:53:00-05:00,RVNC,negative
1110190.0,Revance Therapeutics Announces Proposed Public Offering of Common Stock,2015-11-02 06:09:00-05:00,RVNC,neutral
1110191.0,Revance Therapeutics Announces 3.3M Share Secondary Offering,2015-11-02 06:07:00-05:00,RVNC,positive
1110192.0,Mid-Afternoon Market Update: Rayonier Advanced Materials Gains On Upbeat Results; Rovi Shares Slide,2015-10-29 15:55:00-04:00,RVNC,positive
1110193.0,"Cowen Defends Revance Therapeutics, Advises To Buy On Weakness, Expects RT002 To Yield ~$1B And Would Buy Shares 'aggressively'",2015-10-29 12:35:00-04:00,RVNC,negative
1110194.0,Mid-Day Market Update: Build-A-Bear Declines On Weak Results; Lifelock Shares Surge,2015-10-29 12:29:00-04:00,RVNC,negative
1110195.0,Benzinga's Volume Movers,2015-10-29 10:39:00-04:00,RVNC,neutral
1110196.0,Mid-Morning Market Update: Markets Edge Lower; Mastercard Earnings Beat Estimates,2015-10-29 10:18:00-04:00,RVNC,negative
1110197.0,Morning Market Gainers,2015-10-29 09:47:00-04:00,RVNC,neutral
1110198.0,Benzinga's Top #PreMarket Gainers,2015-10-29 08:44:00-04:00,RVNC,positive
1110199.0,Shares That Spiked Before Close,2015-10-16 16:02:00-04:00,RVNC,positive
1110200.0,Revance Therapeutics Begins Phase 2 Clinical Study of Its Unique Botulinum Toxin Type A for Injection to Treat Cervical Dystonia,2015-09-29 16:02:00-04:00,RVNC,positive
1110201.0,UPDATE: Revance Therapeutics Says Planning to Issue Interim Results from Phase 3 Trial of Botulinum Toxin During 1H'16,2015-09-28 16:04:00-04:00,RVNC,neutral
1110202.0,Revance Therapeutics Begins Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Lateral Canthal Lines,2015-09-28 16:02:00-04:00,RVNC,positive
1110203.0,Revance Therapeutics Starts Phase 2 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis,2015-09-09 16:03:00-04:00,RVNC,positive
1110204.0,Revance Therapeutics Reports Q2 Loss $0.71 Vs Est Loss $0.84,2015-08-06 17:22:00-04:00,RVNC,negative
1110205.0,"Revance Therapeutics Announces Change in Role of Jacob Waugh, M.D.",2015-07-02 16:08:00-04:00,RVNC,neutral
1110206.0,"Jim Cramer Shares His Thoughts On L Brands, Revance Therapeutics And bluebird bio",2015-06-05 07:23:00-04:00,RVNC,positive
1110207.0,"Revance Therapeutics to Initiate Two Key Trials for RT001, Its Topical Botulinum Toxin Type A Investigational Drug Product Candidate",2015-06-03 07:31:00-04:00,RVNC,neutral
1110208.0,Who's The Next Big Pharma Acquisition?,2015-05-29 11:20:00-04:00,RVNC,neutral
1110209.0,"Revance Therapeutics Reports Q1 EPS $(0.65) vs. Est. $(0.74), Rev. $75K vs. Est $130K",2015-05-13 16:06:00-04:00,RVNC,neutral
1110210.0,"8-K from Revance Therapeutics Shows Complaint Filed May 1st Related to City of Warren Police, Fire Systems Retirement Systems, Alleges RT001 Clinical Program Misrepresented",2015-05-04 09:07:00-04:00,RVNC,negative
1110211.0,Filing from Revance Therapeutics Shows Registration for $50M Common Stock Offering,2015-03-19 17:14:00-04:00,RVNC,neutral
1110212.0,S-3 from Revance Therapeutics Shows Registration for $300M Mixed Securities Shelf Offering,2015-03-04 17:19:00-05:00,RVNC,positive
1110213.0,"Revance Therapeutics Reports Q4 EPS $(0.60), Rev. $75k",2015-03-02 16:12:00-05:00,RVNC,neutral
1110214.0,Revance Appoints Dr. Philip Vickers to Its BOD,2015-02-26 17:04:00-05:00,RVNC,neutral
1110215.0,"Revance Therapeutics Offers Update on Definition of Clinical Program Milestones; Expecting FY14 Adj. Operating Expense in $42-$46M Range; Sees FY16 R&D Cost $52-$60M, Cash Burn $74-$84M",2015-01-12 07:07:00-05:00,RVNC,neutral
1110216.0,Revance Therapeutics Announces FY 2014 and FY 2015 Operating expectations,2015-01-12 07:06:00-05:00,RVNC,neutral
1110217.0,13G: Franklin Resources Reports 11.6% Stake In Revance Therapeutics,2015-01-09 13:13:00-05:00,RVNC,neutral
1110218.0,Revance Therapeutics Publishes Positive Results From RT002 Phase 1/2 Study,2015-01-08 16:09:00-05:00,RVNC,positive
1110219.0,Revance Therapeutics Initiates BELMONT Phase 2 Active Comparator Trial of Injectable RT002,2015-01-05 07:06:00-05:00,RVNC,positive
1110220.0,Morning Market Losers,2014-11-13 09:49:00-05:00,RVNC,negative
1110221.0,Revance Therapeutics Provides Update On RT001 Clinical Program For The Lead Indication For Crow's Feet Lines,2014-10-01 16:02:00-04:00,RVNC,neutral
1110222.0,Revance Therapeutics Reports Q2 EPS of $(0.69) vs $(0.68) Est; Revenue of $75.0K vs $100.0K Est,2014-08-12 16:10:00-04:00,RVNC,neutral
1110223.0,UPDATE: Net Proceeds from Revance Offering ~$131.3M,2014-06-24 16:07:00-04:00,RVNC,neutral
1110224.0,Revance Therapeutics Closes Offering of 4.6M Shares at $30.50/Share,2014-06-24 16:07:00-04:00,RVNC,positive
1110225.0,US Stock Futures Flat Ahead Of Jobless Claims,2014-06-19 07:37:00-04:00,RVNC,neutral
1110226.0,"Revance Therapeutics Prices 4M Share Offering at $30,50/Share",2014-06-19 05:36:00-04:00,RVNC,positive
1110227.0,Amended S-1 from Revance Therapeutics Shows Raised Offering Amount from 3M Previously to 4M Shares,2014-06-18 14:36:00-04:00,RVNC,positive
1110228.0,Revance Announces 3M Share Offering,2014-06-16 16:05:00-04:00,RVNC,positive
1110229.0,Revance Therapeutics Reports Q1 EPS of $(1.93) vs $(0.87) Est,2014-05-13 16:10:00-04:00,RVNC,neutral
1110230.0,Mid-Afternoon Market Update: Revance Therapeutics Continues to Rally as Markets Hang onto Early Strength,2014-04-22 16:01:00-04:00,RVNC,positive
1110231.0,Mid-Day Market Update: Allergan Surges On Buyout Offer; Lexmark Shares Slip,2014-04-22 12:14:00-04:00,RVNC,positive
1110232.0,Mid-Morning Market Update: Markets Gain; McDonald's Posts Lower Profit,2014-04-22 10:46:00-04:00,RVNC,positive
1110233.0,Morning Market Movers ,2014-04-22 09:43:00-04:00,RVNC,neutral
1110234.0,Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lines,2014-04-21 16:56:00-04:00,RVNC,positive
1110235.0,Revance Therapeutics Reports Q4 EPS of $(47.11); Revenue of $309.0K vs $100.0K Est,2014-03-26 16:07:00-04:00,RVNC,neutral
1110236.0,"Morning Gainers for Mar. 3, 2014: DNDN, PERI, RVNC, ARRY, OMEX, NIHD",2014-03-03 10:27:00-05:00,RVNC,neutral
1110237.0,"Cowen & Company Initiates Coverage on Revance Therapeutics at Outperform, Announces $55.00 PT",2014-03-03 08:18:00-05:00,RVNC,neutral
1110238.0,"Piper Jaffray Initiates Coverage on Revance Therapeutics at Overweight, Announces $44.00 PT",2014-03-03 08:18:00-05:00,RVNC,negative
1110239.0,"BMO Capital Initiates Coverage on Revance Therapeutics at Outperform, Announces $37.00 PT",2014-03-03 08:17:00-05:00,RVNC,neutral
1110240.0,Benzinga's Top #PreMarket Gainers,2014-03-03 08:07:00-05:00,RVNC,positive
1110241.0,Shares of Revance Therapeutics Open for Trade at $21 After Pricing at Just $16/Share,2014-02-06 11:16:00-05:00,RVNC,positive
1110242.0,"Waiting on Several IPO's This Morning: LADR, EGLT, CMFN, EBIO, RVNC",2014-02-06 09:45:00-05:00,RVNC,neutral
1110243.0,Revance Therapeutics Prices 5M Share IPO at $14-$16/ Share,2014-01-27 06:10:00-05:00,RVNC,positive
